Table 3. Comparison of patients by FIB-4.

Characteristics	Testing Set (n= 108)			Validation Set (n= 324)
	I (n= 70) ≤3.25	II (n = 38) >3.25	P	I (n = 229) ≤3.25	II (n = 95) >3.25	P
Age	48±10.8	57±10.3	0.180	51±11.2	57±10.3	0.102
Gender (male v female)	58 v 12	27 v 11	0.218	196 v 33	80 v 15	0.734
ALT (U/L)	45.76±35.88	57.05±53.51	0.409	49.71±45.35	64.33±110.57	0.917
AST (U/L)	41.04±17.84	64.42±42.20	0.248	36.85±20.18	70.45±87.31	0.001
TB (mg/dL)	0.89±0.44	1.28±0.77	0.391	0.84±0.35	1.14±1.05	0.023
ALB (g/L)	41.97±6.44	38.68±6.51	0.043	44.34±4.39	41.58±4.79	0.003
Creatinine (mg/dL)	0.76±0.16	0.80±0.23	0.452	0.91±0.52	0.92±0.52	0.221
AFP (ng/ml)(≤20 v >20)	30 v 40	18 v 20	0.652	91 v 138	35 v 60	0.707
HBV DNA level (≤105 v >105copies/ml)	34 v 36	15 v 23	0.421	91 v 138	38 v 57	1.000
INR	1.02±0.01	1.14±0.03	0.051	1.00±0.07	1.07±0.10	0.002
Platelet count (109/L)	167.71±54.85	89.39±54.87	<0.001	167.00±57.60	89.47±37.76	0.009
Tumor number (single v multiple)	53 v 17	32 v 6	0.337	196 v 33	87 v 8	0.198
Vascular invasion (yes v no)	24 v 46	24 v 14	0.005	58 v 171	26 v 69	0.404
Tumor encapsulation (yes v no)	17 v 53	5 v 33	0.215	122 v 107	54 v 41	0.624
Tumor size (≤5.0 v >5.0)	34 v 36	14 v 24	0.311	154 v 75	69 v 26	0.360
TNM stage (I-II v III A)	40 v 30	15 v 23	0.107	197 v 32	80 v 15	0.729
Postoperative TACE (yes v no)	30 v 40	15 v 23	0.332	74 v 155	42 v 53	0.417
Re-operation (yes v no)	7 v 63	4 v 34	1.000	15 v 214	13 v 82	0.803

Abbreviations: HBV: hepatitis B virus; HCC: hepatocellular carcinoma; ALT: alanine aminotransferase; AST: aspartate aminotransferase; TB: total bilirubin; ALB: Albumin; INR: international normal ratio; AFP: alpha fetoprotein; TACE: transarterial chemoembolization.